Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B Vaccine

Hepatitis B Clinical Trial

Official title:

Phase IV Immunogenicity and Safety Study of Different Immunization Schedules of Inactivated Hepatitis A Vaccine (HAV) and/ or Combined Hepatitis A and Hepatitis B Vaccine (HABV) in Healthy Chinese Infants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02445703
• Other study ID #: PRO-HAB-4005
• Status: Completed
• Phase: Phase 4
• Start date: May 2014
• Est. completion date: June 2016

Study information

• Verified date: May 2015
• Source: Sinovac Biotech Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the immunogenicity and safety of three different immunization schedules of inactivated hepatitis A vaccine (HAV) and/ or combined hepatitis A and B vaccine (HABV) in healthy Chinese infants.

Description:

This study is a randomized double-blind, single-center, phase IV clinical trial. The purpose of this study is to compare the immunogenicity and safety of three different immunization schedules of inactivated hepatitis A vaccine (HAV) and/ or combined hepatitis A and B vaccine (HABV) in healthy Chinese infants between 18 and 24 months old. The subjects were randomly assigned into 3 groups. Subjects in group 1 each received 2 doses of HAV with a 6-month interval (at day 0 and month 6); subjects in group 2 each received 1 dose of HAV at day 0 and 1 dose of HABV at month 6; subjects in group 3 each received 2 doses of HABV with a 6-month interval (at day 0 and month 6).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 301
• Est. completion date: June 2016
• Est. primary completion date: January 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Months to 24 Months

Eligibility

Inclusion Criteria:

• Healthy infants between 18 and 24 months old;

• Have not received hepatitis A vaccine before;

• Completed hepatitis B vaccine full immunization schedule;

• Written consent of the guardian of each participant;

Exclusion Criteria of the First Injection:

• History of allergy to vaccine(s), or history of serious adverse reaction to vaccination, such as urticaria, dyspnea, angioneurotic edema, or abdominal pain;

• Autoimmune disease or immunodeficiency;

• Any acute disease that made the conditions of the person unsuitable for vaccination

• Administration of any live attenuated vaccine within 14 days prior to the injection;

• Administration of any subunit vaccine or inactivated vaccine within 7 days prior to the injection;

• Administration of treatment of immunosuppressants (e.g., corticosteroid) within 1 month prior to the injection, or planning for such treatment during this study;

• Body temperature > 37.0 °C before injection;

• Based on the evaluation of the investigator, there was any other factor that indicating the person was unsuitable for this study;

Exclusion Criteria of the Second Injection:

• Any acute infectious disease, body temperature > 38.5 °C or acute attacks of chronic diseases within 3 days prior to the second injection;

• Administration of blood product or other investigational drug during this study;

• Occurrence of adverse event at grade 3 or higher and the event was related to the first injection;

• The investigator or the Ethic Committee decided that the subject should be excluded;

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B

Intervention

Biological:
• Inactivated Hepatitis A vaccine (HAV)
Dosage of HAV is 250u hepatitis A antigen/0.5ml/dose.
• Combined hepatitis A and hepatitis B vaccine (HABV)
Dosage of HABV is 250u hepatitis A antigen and 5µg hepatitis B antigen/0.5ml/dose

Locations

Country	Name	City	State
China	Hunan Provincial Center for Disease Control and Prevention	Changsha	Hunan

Sponsors (1)

Lead Sponsor	Collaborator
Sinovac Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Post-immunization Seropositivity Rates (SPR) to Hepatitis A	The post-immunization SPR is the percent of participants with anti-HAV titers = 20 mIU/mL at month 7. Anti-HAV titers were detected in participants' serum samples using electrochemiluminescence immunoassay.	7 months
Secondary	The Post-immunization Geometric Mean Concentration (GMC) of Hepatitis A Antibody (anti-HAV)	The post-immunization GMC values of anti-HAV were measured using electrochemiluminescence immunoassay in serum samples collected at month 7.	7 months
Secondary	The Post-immunization GMC of Hepatitis B Surface Antibody (HBsAb)	The post-immunization GMC values of HBsAb were detected using electrochemiluminescence immunoassay in serum samples collected at month 7.	7 months
Secondary	The Post-immunization SPR to Hepatitis B	The post-immunization SPR is the percent of participants with HBsAb titer = 10 mIU/mL at month 7. HBsAb titers were detected in participants' serum samples using electrochemiluminescence immunoassay.	7 months
Secondary	Occurrence of Adverse Events (AEs)	AE information was collected after first injection (day 0) until month 7. Each AE case was reviewed by the investigator to determine whether or not it was an adverse reaction (related to the vaccination). After each injection, a 30-minute safety observation was conducted immediately, and body temperature and solicited adverse events (AEs) within 72 hours were recorded. Unsolicited AEs information was collected from day 0 (after injection) to month 7.	7 months